In an aging population, the social impact of osteoarthritis (OA) can dramatically increase to become the most common musculoskeletal disease. However, at present, therapies are limited to palliative treatments or surgical intervention alone, since disease-modifying OA (DMOA) drugs are scarce, primarily due to the absence of relevant preclinical models of the disease. As a result, tissue engineers and materials scientists aim to develop in vitro models for reliably predicting the efficacy of the requisite DMOA drugs.
* This article was originally published here
